PUK22 Treatment Adherence and Quality of Life in UK Distal Renal Tubular Acidosis Patients

2021 ◽  
Vol 24 ◽  
pp. S237
Author(s):  
D. Sudusinghe ◽  
I. Dunnett ◽  
J. Mumford ◽  
A. Chrysos ◽  
S. Donald ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Adherence ◽  
Renal Tubular Acidosis ◽  
Distal Renal Tubular Acidosis ◽  
Renal Tubular

scholarly journals P0003ADHERENCE BENEFITS OF ADV7103, AN INNOVATIVE PROLONGED-RELEASE ORAL COMBINATION PRODUCT, IN PATIENTS WITH DISTAL RENAL TUBULAR ACIDOSIS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Aurélia Bertholet-Thomas ◽  
Catherine Guittet ◽  
Maria Asunción Manso-Silván ◽  
Victor Navas Serrano ◽  
Luc André Granier ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Tubular Acidosis ◽  
Potassium Citrate ◽  
Distal Renal Tubular Acidosis ◽  
Prolonged Release ◽  
Open Label ◽  
Advanced Therapy ◽  
Renal Tubular

Abstract Background and Aims Distal renal tubular acidosis (dRTA) is a rare disorder leading to impaired net acid excretion by the kidney inducing hyperchloremic metabolic acidosis and hypokalemia. The therapeutic effect of the standard of care is of short duration and requires multiple day and night administrations; it is also often accompanied by gastrointestinal discomfort and poor palatability impacting medication adherence. ADV7103, the first advanced therapy for dRTA, consists of a combination of prolonged-release potassium citrate and prolonged-release potassium bicarbonate granules providing round-the-clock alkali and potassium coverage with twice daily administration. Long-term adherence with ADV7103 is reported, along with acceptability of the product. Method B22CS is a multicentre, open-label long-term extension study, evaluating safety, tolerability, acceptability and efficacy of ADV7103 in adult and paediatric patients with dRTA. Adherence was assessed at each study visit up to 24 months, based on accountability of study drug retrieval, laboratory results, and interview of the patients in a diary and expressed as the proportion of patients that presented adherence lower than 50%, between 50% and 74%, between 75 and 90%, and higher than to 90%. Treatment acceptability as well as quality of life of the patients and their parents were assessed using a 100-mm visual analogue scales (VAS). Results Table 1 shows the evolution of compliance between Month 6 and Month 24. Overall, of the 29 patients remaining in the study after 24 months, 18 (62%) had adherence rates >90%, 5 (17%) had adherence rates of 75-90%, 6 (21%) had adherence rates of 50-74%, and there were no patients with adherence <50%. Adherence was good in all age groups, with rates of ≥75% in 100% of adults, 63% of adolescents 85% of children, and 67% of infants and toddlers. Compared to the alkalising treatments they had before the study, more than 80% of the patients perceived both the improvement of the formulation and of the number of daily doses at scores ≥ 75 mm. The overall improvement of quality of life reported by the patients was of 89 ± 19 mm and that reported by their parents was of 90 ± 14 mm after 24 months of treatment. Conclusion Adherence to treatment was maintained at a high level throughout the 24 months of the study confirming the good acceptance of ADV7103 therapy.

scholarly journals Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis

2021 ◽  
Author(s):  
Aurélia Bertholet-Thomas ◽  
Catherine Guittet ◽  
Maria A. Manso-Silván ◽  
Sophie Joukoff ◽  
Victor Navas-Serrano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Tubular Acidosis ◽  
Distal Renal Tubular Acidosis ◽  
Adult Patients ◽  
Prolonged Release ◽  
Open Label ◽  
Plasma Bicarbonate ◽  
Normal Ranges ◽  
Renal Tubular

Abstract Background A new prolonged-release formulation of potassium citrate and potassium bicarbonate, ADV7103, has been shown to improve metabolic control, palatability, and gastrointestinal safety in patients with distal renal tubular acidosis (dRTA) when compared to standard of care (SoC) treatments. The present work evaluates safety and efficacy of ADV7103 during 24 months. Methods Thirty pediatric and adult patients were included in an open-label extension study after a phase II/III trial. Safety and tolerability were assessed. Plasma bicarbonate and potassium levels, as well as urine parameters, were evaluated over time. Acceptability, adherence, and quality of life were also assessed. The evolution of clinical consequences of dRTA in the cohort was explored. Results There were 104 adverse events (AEs) reported, but only 9 gastrointestinal events observed in five patients (17%) were considered to be related to ADV7103 treatment. There were no AEs leading to treatment discontinuation. Plasma bicarbonate and potassium levels were in the normal ranges at the different visits, respectively, in 69–86% and 83–93% of patients. Overall adherence rates were ≥ 75% throughout the whole study in 79% patients. An average improvement of quality of life of 89% was reported at 24 months of study. Conclusions Common AEs concerned metabolism and gastrointestinal disorders; the former being related to the disease. Less than half of the gastrointestinal AEs were related to ADV7103 treatment and they were mostly mild in severity. Metabolic parameters were maintained in the normal ranges in most patients. Patient satisfaction was high and adherence to treatment was good and remained stable. Trial registration number Registered as EudraCT 2013-003828-36 on the 3rd of September 2013. Graphical Abstract

PRO9 ADV7103 Treatment Adherence in Patients with Distal Renal Tubular Acidosis (DRTA)

2021 ◽  
Vol 24 ◽  
pp. S199
Author(s):  
P. Goodyer ◽  
M. Manso ◽  
C. Guittet ◽  
A. Bertholet-Thomas
Keyword(s):  
Treatment Adherence ◽  
Renal Tubular Acidosis ◽  
Distal Renal Tubular Acidosis ◽  
Renal Tubular

Distal Renal Tubular Acidosis Associated with Concurrent Leptospirosis in a Dog

2014 ◽  
Vol 50 (3) ◽  
pp. 203-208 ◽  
Author(s):  
Stephen A. Martinez ◽  
Roger A. Hostutler
Keyword(s):  
Metabolic Acidosis ◽  
Renal Tubular Acidosis ◽  
Clinical Signs ◽  
Distal Renal Tubular Acidosis ◽  
The Other ◽  
Laboratory Evaluation ◽  
Alkaline Urine ◽  
Alkali Therapy ◽  
Renal Tubular

A 9 yr old spayed female boxer was presented for evaluation of vomiting, lethargy, anorexia, and weight loss. Initial laboratory evaluation revealed a hyperchloremic normal anion gap metabolic acidosis with alkaline urine that was consistent with a diagnosis of distal renal tubular acidosis (RTA). Targeted therapy was initiated with Na bicarbonate (HCO3) and potassium (K) gluconate. Leptospirosis was subsequently diagnosed with paired microagglutination testing (MAT), and doxycycline was added to the other treatments. Clinical signs resolved, and 6 mo after diagnosis, although the dog remained on alkali therapy (i.e., NaHCO3 and K gluconate) and a mild metabolic acidosis persisted, the dog remained otherwise healthy with a good quality of life. To the authors’ knowledge, this is the first report to describe the concomitant association of those two disorders. Leptospirosis should be considered for any case of RTA in dogs.

A Novel Mutation in the Anion Exchanger 1 Gene Is Associated With Familial Distal Renal Tubular Acidosis and Nephrocalcinosis

PEDIATRICS ◽  
2003 ◽  
Vol 112 (6) ◽  
pp. 1361-1367 ◽  
Author(s):  
L. Cheidde ◽  
T. C. Vieira ◽  
P. R. M. Lima ◽  
S. T. O. Saad ◽  
I. P. Heilberg
Keyword(s):  
Renal Tubular Acidosis ◽  
Anion Exchanger ◽  
Novel Mutation ◽  
Distal Renal Tubular Acidosis ◽  
Anion Exchanger 1 ◽  
Renal Tubular

Key facts on moderate to severe acute pain combined treatment with tramadol and dexketoprofen at fixed doses

2020 ◽  
Vol 13 (3) ◽  
pp. 304-310
Author(s):  
Jarosław Woroń
Keyword(s):  
Quality Of Life ◽  
Treatment Adherence ◽  
Acute Pain ◽  
Pain Treatment ◽  
Combined Treatment ◽  
Physiological Changes ◽  
Physiological Mechanisms ◽  
Pain Mechanisms ◽  
Proven Efficacy

The development of pain is associated with numerous physiological mechanisms. Improper acute pain treatment significantly reduces the quality of life and leads to a number of physiological changes that adversely affect the general condition of the patient. In many cases, inadequate analgesic therapy results in the transition from acute to chronic pain. For this reason, it is extremely important to use drugs that synergistically affect various pain mechanisms. Combined preparations, including the combination of tramadol and dexketoprofen, are very effective. This combination has many advantages, including proven efficacy and tolerability, ensures better treatment adherence and is easy to administer.

Bone mineral density and histology in distal renal tubular acidosis

2001 ◽  
Vol 59 (3) ◽  
pp. 1086-1093 ◽  
Author(s):  
Somnuek Domrongkitchaiporn ◽  
Chonlatrip Pongsakul ◽  
Wasana Stitchantrakul ◽  
Vorachai Sirikulchayanonta ◽  
Boonsong Ongphiphadhanakul ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Renal Tubular Acidosis ◽  
Distal Renal Tubular Acidosis ◽  
Mineral Density ◽  
Renal Tubular

Genotypic and phenotypic analysis in 51 Chinese patients with primary distal renal tubular acidosis

2021 ◽  
Author(s):  
Wencong Guo ◽  
Qijing Song ◽  
Ruixiao Zhang ◽  
Qing Xin ◽  
Zhiying Liu ◽  
...  
Keyword(s):  
Renal Tubular Acidosis ◽  
Distal Renal Tubular Acidosis ◽  
Chinese Patients ◽  
Phenotypic Analysis ◽  
Renal Tubular

scholarly journals Distal Renal Tubular Acidosis in Mice Lacking the AE1 (Band3) Cl−/HCO3−Exchanger (slc4a1)

2007 ◽  
Vol 18 (5) ◽  
pp. 1408-1418 ◽  
Author(s):  
Paul A. Stehberger ◽  
Boris E. Shmukler ◽  
Alan K. Stuart-Tilley ◽  
Luanne L. Peters ◽  
Seth L. Alper ◽  
...  
Keyword(s):  
Renal Tubular Acidosis ◽  
Distal Renal Tubular Acidosis ◽  
Renal Tubular
Sign in / Sign up

Export Citation Format

Share Document